{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:28Z","timestamp":1788013348767,"version":"build-2784847793"},"reference-count":30,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johnson &amp; Johnson"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal proliferation of plasma cells that leads to bone disease, including lytic lesions and osteoporosis [...]<\/jats:p>","DOI":"10.3390\/cancers17091389","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T20:11:48Z","timestamp":1745352708000},"page":"1389","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Treatment Outcomes of Different Sequencing Options with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Transplant-Ineligible Multiple Myeloma in Japan"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0300-378X","authenticated-orcid":false,"given":"Kazuhito","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0863-0522","authenticated-orcid":false,"given":"Yuma","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo 101-0065, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-6669","authenticated-orcid":false,"given":"Chika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo 101-0065, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-7298","authenticated-orcid":false,"given":"Hiroaki","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo 101-0065, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-5869","authenticated-orcid":false,"given":"Yosuke","family":"Koroki","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo 101-0065, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bernstein, Z.S., Kim, E.B., and Raje, N. (2022). Bone Disease in multiple myeloma: Biologic and clinical implications. Cells, 11.","DOI":"10.3390\/cells11152308"},{"key":"ref_2","unstructured":"Japanese Society of Hematology (2024, August 15). JSH Practical Guidelines for Hematological Malignancies, 2023: III Myeloma: 1. Multiple My-eloma (MM) 2023. (In Japanese)."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Handa, H., Ishida, T., Ozaki, S., Mori, A., Kato, K., and Iida, S. (2023). Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0283931"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1002\/cam4.4137","article-title":"Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019","volume":"10","author":"Kumar","year":"2021","journal-title":"Cancer Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-019-03858-w","article-title":"Treatment evolution and improved survival in multiple myeloma in Taiwan","volume":"99","author":"Tang","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s12185-024-03754-8","article-title":"Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016\u20132021)","volume":"119","author":"Shibayama","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fonseca, R., Usmani, S.Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E.M., and Nair, S. (2020). Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07503-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tang, W., Yang, J., Li, Y., Zhang, L., Li, H., Wang, J., Liao, Y., Zhang, C., Qu, Y., and Zheng, Y. (2023). Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.979111"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Atrash, S., Thompson-Leduc, P., Tai, M.-H., Kaila, S., Gray, K., Ghelerter, I., Lafeuille, M.-H., Lefebvre, P., and Rossi, A. (2021). Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: A real-world chart review study. BMC Cancer, 21, Erratum in BMC Cancer 2021, 21, 1291.","DOI":"10.1186\/s12885-021-08881-7"},{"key":"ref_12","unstructured":"Adis Insight (2024, October 23). Daratumumab\u2014Janssen Biotech. Available online: https:\/\/adisinsight.springer.com\/drugs\/800022454."},{"key":"ref_13","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, December 02). List of Approved Products. Available online: https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Iida, S., Yasutomi, Y., Samyshkin, Y., Chen, Y.-C., Chen, C.-C., Lee, W.S., Kim, S.-W., McGuiness, C., Zhou, Z., and McNamara, S. (2025). Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0315932"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","article-title":"Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma","volume":"28","author":"Fonseca","year":"2023","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","article-title":"Context and considerations for use of two Japanese real-world databases in Japan: Medical data vision and Japanese medical data center","volume":"9","author":"Laurent","year":"2022","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_23","unstructured":"Medical Data Vision (2025, April 01). MDV Database Overview. Available online: https:\/\/en.mdv.co.jp\/ebm\/about-mdv-database\/mdv-database-overview\/."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","article-title":"Overview of Sankey flow diagrams: Focusing on symptom trajectories in older adults with advanced cancer","volume":"13","author":"Otto","year":"2022","journal-title":"J. Geriatr. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.46989\/001c.124362","article-title":"Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study","volume":"6","author":"Tso","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Horigome, Y., Suzuki, K., and Suzuki, T. (2024). Daratumumab Treatment for \u201cTruly Frail\u201d Elderly Myeloma Patients. Life, 14.","DOI":"10.3390\/life14030389"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/ejh.14392","article-title":"Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes","volume":"114","author":"Perrot","year":"2025","journal-title":"Eur. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1389\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:19:21Z","timestamp":1760030361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cancers17091389"],"URL":"https:\/\/doi.org\/10.3390\/cancers17091389","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}